Chaganti, R.S.K., and Nanjangud, G. Cytogenetics of lymphoma. In: Non-Hodgkin's lymphomas (Mauch, P.M., Armitage, J.O., Coiffier, B., and Dalla-Favera, R., Harris, N.L., eds.) Lippincott, Williams & Wilkins, Baltimore, pp809-824, 2003.
Pasqualucci, L., Migliazza, A., Chaganti, R.S.K., Ye, H. B., and Dalla-Favera, R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 101: 2914-2923, 2003.
Teruya-Feldstein, J., Donnelly, G., Goy, A., Hegde, A., Nanjangud, G., Qin, J., Thaler, H., Gillies, F., Dyomin, V.G., Lloyd, K.O., Zelenetz, A.D., Houldsworth, J., and Chaganti, R.S.K. MUC-1 mucin expression correlates with advanced stage disease, adverse event-free and overall survival in diffuse large B-cell lymphoma. Appl. Immunohistochem. Mol. Morph. 11:28-32, 2003.
Houldsworth, J., Olshen, A.B., Cattoretti, G., Donnelly, G.B., Teruya-Feldstein, J., Qin, J., Palanisamy, N., Shen, Y., Dyomina, K., Petlakh, M., Pan, Q., Zelenetz, A.D., and Chaganti, R.S.K. Relationship between REL amplification, REL function, and clinical and biological feaures of diffuse large B-cell lymphoma. Blood. 103: 1862-1868, 2004.
Koul, S., McKiernan, J.M., Narayan, G., Houldsworth, J., Bacik, J., Dobrzynski, D.L., Assad, A.M., Manshukani, M., Reuter, V.E., Bosl, G.J., Chaganti, R.S.K., and Murty, V.V.V.S. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol. Cancer 3:16.
Schmidt, H.H., Dyomin, V., Palanisamy, N., Itoyama, T., Nanjangud, G., Pric-Danoewinata, H., Haas, O.A., Chaganti, R.S.K. Deregulation of the carbohydrate (chondroitin 4) sulfotransferase II (CHSTII) gene in B-cellchronic lymphocytic leukemia with a t(12;14)(q23;q32). Oncogene. 23: 6991-6996, 2004.
Chadalavada, R.S., Houldsworth, J., Olshen, A.B., Bosl, G.J., Studer, L., Chaganti, R.S.K. Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent embryonal carcinoma cells. Funct. Integr. Genomics. 5: 59-69, 2005.
Houldsworth, J., Bosl, G.J., and Chaganti, R.S.K. Genetics and biology of adult male germ cell tumors. In: Urological Cancers: Science and Treatment (Waxman, J., ed) Springer Verlag, London, pp221-229, 2005.
Korkola, J.E., Houldsworth, J., Dobrzynski, D., Olshen, A.B., Reuter, V.E., Bosl, G.J., and Chaganti, R.S. Gene expression-based classification of nonseminomatous male germ cell tumors. Oncogene 28: 5101-5107, 2005.
Banerjee, D., Chadalavada, R.S.V., Bourdon, V., Korkola, J.E., Motzer, R.J., and Chaganti, R.S.K. Transcriptional program associated with IFN-á response of renal cell carcinoma. J. Interferon & Cytokine Res. 26: 156-170, 2006.
Chaganti, R.S.K. Testicular cancer. In: Encyclopedia of Life Sciences. John Wily & Sons, Ltd: Chichester, 2006.
Chen, W., Houldsworth, J., Olshen, A.B., Nanjangud, G., Chaganti, S., Venkataraman, E.S., Halaas, J., Teruya-Feldstein, J., Zelenetz, A.D., and Chaganti, R.S.K. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large cell lymphomas. Blood 107:2477-2485, 2006.
Houldsworth, J., Bosl, G.J., and Chaganti, R.S.K. Biology and genetics of adult male germ cell tumors. In: Comprehensive Textbook of Genitourinary Oncology, Third Edition (Vogelzanf, N.J., Scardino, P.T., Shipley, W.U., Debruyne, M.J., Linehan, M., eds), Baltimore, Lippincott Williams & Wilkins, New York, pp563-571, 2005.
Houldsworth J., Korkola, J.E., Bosl, G.J., Chaganti, R.S.K. Biology and genetics of adult male germ cell tumors. J. Clin. Oncol. 24: 5512-5518, 2006.
Korkola, J.E., Houldsworth, J., Chadalavada, R., Olshen A.B., Dobrzynski, D., Reuter, V.E., Bosl, G.J., and Chaganti, R.S.K. Down-regulation of stem cell genes, including those in a 200kb gene cluster at 12p13.31 is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 66:820-827, 2006.
Patel, P.H., Chadalavada, S.V., Chaganti, R.S.K., Motzer, R.J. Targeting VHL pathway in renal cell carcinoma. Clin. Cancer Res. 12: 7215-7220, 2006.
Chadalavada, R.S.V., Korkola, J.E., Houldsworth, J., Olshen, A.B., Bosl, G.J., Studer, L., Chaganti, R.S.K. Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 embryonal carcinoma cells. Stem Cells 25: 771-8, 2007.
Chaganti, R.S.K. Genetics of cancer. In: Cecil Medicine. 23rd Edition. Saunders, Elsevier, Philadelphia, pp1340-1344, 2007.
Narayan G., Bourdon, V., Chaganti, S., Arias-Pudilo, H., Nandulu, S.V., Rao, P.H., Gissmann, L., Durst, M., Schneider, A., Pothuri, B., Mansukhani, M., Basso, K., Chaganti, R.S.K., Murty, V.V. Gene dosage alterations revealed by cDNA microarrys analysis in cervical cancer: Identification of candidate amplified and overexpressed genes. Genes, Chromosomes & Cancer 46: 373-384, 2007.
Nanjangud, G., Rao, P.H., Teruya-Feldstein, J., Donnelly, G., Qin, J., Mehra, S., Jhanwar, S.C., Zelenetz, A.D., Chaganti, R.S.K. Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative sub sets and histologic progression. Cytogenet. Genome Res. 118: 337-344, 2007.
Korkola, J.E., Heck, S., Olshen, A.B., Reuter, V.E., Bosl, G.J., Houldsworth, J., Chaganti, R.S.K. In vivo differentiation and genomic evolution in adult male germ cell tumors. Genes, Chromosomes and Cancer 47: 43-55, 2008.
Bosl, G.J., Bajorin, D.F., Sheinfeld, J., Motzer, R.J., Chaganti, R.S.K. Testis Cancer. In: DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. Eighth Edition (DeVita, V.T., Lawrence, T.S., Rosenberg, S.A., eds). Lippincott Williams & Wilkins, Philadelphia pp 1463-1485.
Houldsworth, J., Petlakh, M., Olshen, A.B., and Chaganti, R.S.K. Pathway activation in large B-Cell non-Hodgkin's lymphoma cell lines by doxorubicin reveals prognostic markers of In Vivo response. Leukemia & Lymphoma (in press)
Nanjangud, G., Palanisamy, N., and Chaganti, R.S.K. Cytogenetic analysis and related techniques in hematopathology. (Jaffe, E.S., Harris, N.L., Vardiman, J.W., eds), New York (In press).
analysis (uh-NA-lih-sis)
A process in which anything complex is separated into simple or less complex parts.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)cancer (KAN-ser)
A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Cancer cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of cancer. Carcinoma is a cancer that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a cancer that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are cancers that begin in the cells of the immune system. Central nervous system cancers are cancers that begin in the tissues of the brain and spinal cord. Also called malignancy.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)cell (sel)
The individual unit that makes up the tissues of the body. All living things are made up of one or more cells.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)cytogenetics (SY-toh-jeh-NEH-tix)
The study of chromosomes and chromosomal abnormalities.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)doxorubicin (DOK-soh-ROO-bih-sin)
A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. Doxorubicin comes from the bacterium . It damages DNA and may kill cancer cells. It is a type of anthracycline antitumor antibiotic. Also called Adriamycin PFS, Adriamycin RDF, doxorubicin hydrochloride, hydroxydaunorubicin, and Rubex.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)genetics (jeh-NEH-tix)
The study of genes and heredity. Heredity is the passing of genetic information and traits (such as eye color and an increased chance of getting a certain disease) from parents to offspring.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)germ (jerm)
A bacterium, virus, or other microorganism that can cause infection and disease.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)germ cell (jerm sel)
A reproductive cell of the body. Germ cells are egg cells in females and sperm cells in males.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)in vivo (in VEE-voh)
In the body. The opposite of in vitro (outside the body or in the laboratory).
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)L
A measure of volume for a liquid, using the metric system. One L is equal to 1,000 cubic centimeters (cc), 1,000 milliliters (mm), or 1.0567 quarts (qt). Also called liter.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)leukemia (loo-KEE-mee-uh)
Cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers of blood cells to be produced and enter the bloodstream.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)lymphoma (lim-FOH-muh)
Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)M
In chemistry, M is the amount of a substance that has 6.023 x 10(23) atoms or molecules of that substance. Also called mole (chemical).
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)medicine (MEH-dih-sin)
Refers to the practices and procedures used for the prevention, treatment, or relief of symptoms of a diseases or abnormal conditions. This term may also refer to a legal drug used for the same purpose.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)oncology (on-KAH-loh-jee)
The study of cancer.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)response (reh-SPONTS)
In medicine, an improvement related to treatment.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)testis (TES-tis)
One of two egg-shaped glands inside the scrotum that produce sperm and male hormones. Also called testicle.
Source: The National Cancer Institute's Dictionary of Cancer Terms
(http://www.cancer.gov/dictionary)
